These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 23536694)

  • 1. Transgenic parasites stably expressing full-length Plasmodium falciparum circumsporozoite protein as a model for vaccine down-selection in mice using sterile protection as an endpoint.
    Porter MD; Nicki J; Pool CD; DeBot M; Illam RM; Brando C; Bozick B; De La Vega P; Angra D; Spaccapelo R; Crisanti A; Murphy JR; Bennett JW; Schwenk RJ; Ockenhouse CF; Dutta S
    Clin Vaccine Immunol; 2013 Jun; 20(6):803-10. PubMed ID: 23536694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine.
    McCoy ME; Golden HE; Doll TA; Yang Y; Kaba SA; Zou X; Gerbasi VR; Burkhard P; Lanar DE
    Malar J; 2013 Apr; 12():136. PubMed ID: 23607541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sporozoite neutralizing antibodies elicited in mice and rhesus macaques immunized with a Plasmodium falciparum repeat peptide conjugated to meningococcal outer membrane protein complex.
    Przysiecki C; Lucas B; Mitchell R; Carapau D; Wen Z; Xu H; Wang XM; Nahas D; Wu C; Hepler R; Ottinger E; Ter Meulen J; Kaslow D; Shiver J; Nardin E
    Front Cell Infect Microbiol; 2012; 2():146. PubMed ID: 23226683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of the Immunodominant CD8
    Gibbins MP; Müller K; Glover M; Liu J; Putrianti ED; Bauza K; Reyes-Sandoval A; Matuschewski K; Silvie O; Hafalla JCR
    Infect Immun; 2020 Sep; 88(10):. PubMed ID: 32719159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
    Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
    Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein.
    Raghunandan R; Mayer BT; Flores-Garcia Y; Gerber MW; Gottardo R; Jhun H; Herrera SM; Perez-Ramos DW; Locke E; King CR; Zavala F
    Malar J; 2020 Mar; 19(1):113. PubMed ID: 32183833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine.
    Kaba SA; McCoy ME; Doll TA; Brando C; Guo Q; Dasgupta D; Yang Y; Mittelholzer C; Spaccapelo R; Crisanti A; Burkhard P; Lanar DE
    PLoS One; 2012; 7(10):e48304. PubMed ID: 23144750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.
    Khan F; Porter M; Schwenk R; DeBot M; Saudan P; Dutta S
    PLoS One; 2015; 10(11):e0142035. PubMed ID: 26571021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategic Variants of CSP Delivered as SynDNA Vaccines Demonstrate Heterogeneity of Immunogenicity and Protection from
    Reeder SM; Bah MA; Tursi NJ; Brooks RC; Patel A; Esquivel R; Eaton A; Jhun H; Chu J; Kim K; Xu Z; Zavala F; Weiner DB
    Infect Immun; 2021 Sep; 89(10):e0072820. PubMed ID: 34152830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended protection capabilities of an immature dendritic-cell targeting malaria sporozoite vaccine.
    Luo K; Zavala F; Gordy J; Zhang H; Markham RB
    Vaccine; 2017 Apr; 35(18):2358-2364. PubMed ID: 28342669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-investigation of the circumsporozoite protein-based induction of sterile immunity against Plasmodium berghei infection.
    Reed RC; Louis-Wileman V; Wells RL; Verheul AF; Hunter RL; Lal AA
    Vaccine; 1996 Jun; 14(8):828-36. PubMed ID: 8817831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
    Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
    PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A highly infectious Plasmodium yoelii parasite, bearing Plasmodium falciparum circumsporozoite protein.
    Zhang M; Kaneko I; Tsao T; Mitchell R; Nardin EH; Iwanaga S; Yuda M; Tsuji M
    Malar J; 2016 Apr; 15():201. PubMed ID: 27068454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irradiated sporozoite vaccination induces sex-specific immune responses and protection against malaria in mice.
    Vom Steeg LG; Flores-Garcia Y; Zavala F; Klein SL
    Vaccine; 2019 Jul; 37(32):4468-4476. PubMed ID: 31262583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum.
    Radin K; Clement F; Jongert E; Sterckx YG; Ockenhouse C; Regules J; Lemiale F; Leroux-Roels G
    Malar J; 2016 Nov; 15(1):543. PubMed ID: 27825382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate.
    Noe AR; Espinosa D; Li X; Coelho-Dos-Reis JG; Funakoshi R; Giardina S; Jin H; Retallack DM; Haverstock R; Allen JR; Vedvick TS; Fox CB; Reed SG; Ayala R; Roberts B; Winram SB; Sacci J; Tsuji M; Zavala F; Gutierrez GM
    PLoS One; 2014; 9(9):e107764. PubMed ID: 25247295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a Plasmodium berghei transgenic parasite expressing the full-length Plasmodium vivax circumsporozoite VK247 protein for testing vaccine efficacy in a murine model.
    Mizutani M; Fukumoto S; Soubeiga AP; Soga A; Iyori M; Yoshida S
    Malar J; 2016 Apr; 15(1):251. PubMed ID: 27129682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-species immunity following immunization with a circumsporozoite protein-based vaccine for malaria.
    Yadava A; Nurmukhambetova S; Pichugin AV; Lumsden JM
    J Infect Dis; 2012 May; 205(9):1456-63. PubMed ID: 22457289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rhesus macaque and mouse models for down-selecting circumsporozoite protein based malaria vaccines differ significantly in immunogenicity and functional outcomes.
    Phares TW; May AD; Genito CJ; Hoyt NA; Khan FA; Porter MD; DeBot M; Waters NC; Saudan P; Dutta S
    Malar J; 2017 Mar; 16(1):115. PubMed ID: 28288639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Plasmodium berghei challenge models for the evaluation of pre-erythrocytic malaria vaccines and their effect on perceived vaccine efficacy.
    Leitner WW; Bergmann-Leitner ES; Angov E
    Malar J; 2010 May; 9():145. PubMed ID: 20507620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.